vs
Side-by-side financial comparison of Brookfield Infrastructure Corp (BIPC) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $866.0M, roughly 1.4× Brookfield Infrastructure Corp). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -35.7%, a 52.7% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -4.6%).
Brookfield Infrastructure Partners L.P. is a publicly traded limited partnership with corporate headquarters in Toronto, Canada, that engages in the acquisition and management of infrastructure assets on a global basis.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
BIPC vs JAZZ — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $866.0M | $1.2B |
| Net Profit | $-309.0M | $203.5M |
| Gross Margin | 65.0% | — |
| Operating Margin | 62.7% | 21.2% |
| Net Margin | -35.7% | 17.0% |
| Revenue YoY | -4.6% | 10.1% |
| Net Profit YoY | -148.1% | 6.5% |
| EPS (diluted) | — | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $866.0M | $1.0B | ||
| Q1 25 | — | $897.8M | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $908.0M | $1.0B | ||
| Q1 24 | — | $902.0M |
| Q4 25 | — | $203.5M | ||
| Q3 25 | — | $251.4M | ||
| Q2 25 | $-309.0M | $-718.5M | ||
| Q1 25 | — | $-92.5M | ||
| Q4 24 | — | $191.1M | ||
| Q3 24 | — | $215.1M | ||
| Q2 24 | $643.0M | $168.6M | ||
| Q1 24 | — | $-14.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 63.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 21.2% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | 62.7% | -65.6% | ||
| Q1 25 | — | -6.2% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | 61.9% | 19.5% | ||
| Q1 24 | — | 7.3% |
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | -35.7% | -68.7% | ||
| Q1 25 | — | -10.3% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | — | 20.4% | ||
| Q2 24 | 70.8% | 16.5% | ||
| Q1 24 | — | -1.6% |
| Q4 25 | — | $3.34 | ||
| Q3 25 | — | $4.08 | ||
| Q2 25 | — | $-11.74 | ||
| Q1 25 | — | $-1.52 | ||
| Q4 24 | — | $2.97 | ||
| Q3 24 | — | $3.42 | ||
| Q2 24 | — | $2.49 | ||
| Q1 24 | — | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $1.4B |
| Total DebtLower is stronger | — | $5.4B |
| Stockholders' EquityBook value | $2.2B | $4.3B |
| Total Assets | $23.9B | $11.7B |
| Debt / EquityLower = less leverage | — | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | $466.0M | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $2.2B | $3.7B | ||
| Q1 25 | — | $4.2B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.2B | ||
| Q2 24 | $3.5B | $3.8B | ||
| Q1 24 | — | $3.7B |
| Q4 25 | — | $11.7B | ||
| Q3 25 | — | $11.4B | ||
| Q2 25 | $23.9B | $10.9B | ||
| Q1 25 | — | $11.5B | ||
| Q4 24 | — | $12.0B | ||
| Q3 24 | — | $12.3B | ||
| Q2 24 | $23.7B | $11.4B | ||
| Q1 24 | — | $11.3B |
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $478.0M | $362.5M |
| Free Cash FlowOCF − Capex | — | $345.8M |
| FCF MarginFCF / Revenue | — | 28.9% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $362.5M | ||
| Q3 25 | — | $474.6M | ||
| Q2 25 | $478.0M | $88.9M | ||
| Q1 25 | — | $429.8M | ||
| Q4 24 | — | $398.6M | ||
| Q3 24 | — | $398.7M | ||
| Q2 24 | $511.0M | $331.4M | ||
| Q1 24 | — | $267.2M |
| Q4 25 | — | $345.8M | ||
| Q3 25 | — | $459.4M | ||
| Q2 25 | — | $75.9M | ||
| Q1 25 | — | $415.9M | ||
| Q4 24 | — | $385.3M | ||
| Q3 24 | — | $388.0M | ||
| Q2 24 | — | $324.3M | ||
| Q1 24 | — | $260.3M |
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 40.8% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 35.4% | ||
| Q3 24 | — | 36.8% | ||
| Q2 24 | — | 31.7% | ||
| Q1 24 | — | 28.9% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | 1.78× | ||
| Q3 25 | — | 1.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | 0.79× | 1.97× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIPC
Segment breakdown not available.
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
